Kathleen Squires

TitleProfessor
InstitutionThomas Jefferson University
DepartmentInfectious Diseases
Address1101 Market Street
Philadelphia PA 19107
vCardDownload vCard

    Collapse Research 
    Collapse research activities and funding
    U01AI027673     (SATTLER, FRED R)Jun 30, 1986 - Dec 31, 2006
    NIH
    ADULT AIDS CLINICAL TRIALS UNIT (ACTU)
    Role: Co-Principal Investigator

    U01AI069464     (SQUIRES, KATHLEEN E.)Feb 15, 2007 - Jan 31, 2014
    NIH
    Quintiles Clinical Trial Unit for HIV/AIDS Clinical Trials Networks
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Orkin C, Squires KE, Molina JM, Sax PE, Sussmann O, Lin G, Kumar S, Hanna GJ, Hwang C, Martin E, Teppler H. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial. Clin Infect Dis. 2020 Dec 18. PMID: 33336698.
      Citations:    
    2. Farr Zuend C, Noel-Romas L, Hoger S, Mccorriser S, Westmacott G, Marrazzo J, Hillier SL, Dezzutti C, Squires K, Bunge KE, Burgener A. Influence of dapivirine vaginal ring use on cervicovaginal immunity and functional microbiome in adolescent girls. AIDS. 2020 Nov 11. PMID: 33181534.
      Citations:    
    3. Bunge KE, Levy L, Szydlo DW, Zhang J, Gaur AH, Reirden D, Mayer KH, Futterman D, Hoesley C, Hillier SL, Marzinke MA, Hendrix CW, Gorbach PM, Wilson CM, Soto-Torres L, Kapogiannis B, Nel A, Squires KE. Brief Report: Phase IIa Safety Study of a Vaginal Ring Containing Dapivirine in Adolescent Young Women. J Acquir Immune Defic Syndr. 2020 Feb 01; 83(2):135-139. PMID: 31929401.
      Citations:    
    4. Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Rodgers A, Lupinacci L, Kumar S, Sklar P, Hanna GJ, Hwang C, Martin EA. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial. Lancet HIV. 2020 Jan; 7(1):e16-e26. PMID: 31740348.
      Citations:    
    5. Thompson M, Orkin C, Molina JM, Sax P, Cahn P, Squires K, Xu X, Rodgers A, Kumar S, Teppler H, Martin E, Hanna G, Hwang C. Once-Daily Doravirine for Initial Treatment of Adults Living With HIV-1: An Integrated Safety Analysis. Clin Infect Dis. 2019 May 23. PMID: 31121013.
      Citations:    
    6. Orkin C, Squires KE, Molina JM, Sax PE, Wong WW, Sussmann O, Kaplan R, Lupinacci L, Rodgers A, Xu X, Lin G, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C, Martin EA. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial. Clin Infect Dis. 2018 Aug 31. PMID: 30184165.
      Citations:    
    7. Cahn P, Sax PE, Squires K, Molina JM, Ratanasuwan W, Rassool M, Bloch M, Xu X, Zhou Y, Homony B, Hepler D, Teppler H, Hanna GJ, Nguyen BY, Greaves W. Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial. J Acquir Immune Defic Syndr. 2018 Aug 15; 78(5):589-598. PMID: 29771789.
      Citations:    
    8. Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Xu X, Rodgers A, Lupinacci L, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. Lancet HIV. 2018 Mar 23. PMID: 29592840.
      Citations:    
    9. Hodder S, Squires K, Kityo C, Hagins D, Avihingsanon A, Kido A, Jiang S, Kulkarni R, Cheng A, Cao H. Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/Taf) in Virologically Suppressed Women. J Acquir Immune Defic Syndr. 2018 Feb 21. PMID: 29481486.
      Citations:    
    10. Cahn P, Kaplan R, Sax PE, Squires K, Molina JM, Avihingsanon A, Ratanasuwan W, Rojas E, Rassool M, Bloch M, Vandekerckhove L, Ruane P, Yazdanpanah Y, Katlama C, Xu X, Rodgers A, East L, Wenning L, Rawlins S, Homony B, Sklar P, Nguyen BY, Leavitt R, Teppler H. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. Lancet HIV. 2017 Nov; 4(11):e486-e494. PMID: 28918877.
      Citations:    
    11. Squires KE, Young B, Santiago L, Dretler RH, Walmsley SL, Zhao HH, Pakes GE, Ross LL, Shaefer MS. Response by gender of HIV-1-infected subjects treated with abacavir/lamivudine plus atazanavir, with or without ritonavir, for 144 weeks. HIV AIDS (Auckl). 2017; 9:51-61. PMID: 28424561.
      Citations:    
    12. Squires K, Bekker LG, Katlama C, Yazdanpanah Y, Zhou Y, Rodgers AJ, DiNubile MJ, Sklar PA, Leavitt RY, Teppler H. Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK Studies. Open Forum Infect Dis. 2017; 4(1):ofw047. PMID: 28480227.
      Citations:    
    13. Squires K, Kityo C, Hodder S, Johnson M, Voronin E, Hagins D, Avihingsanon A, Koenig E, Jiang S, White K, Cheng A, Szwarcberg J, Cao H. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study. Lancet HIV. 2016 Sep; 3(9):e410-20. PMID: 27562742.
      Citations:    
    14. Young B, Squires KE, Tashima K, Henry K, Schneider S, LaMarca A, Zhao HH, Ross LL, Shaefer MS. Estimated glomerular filtration rates through 144?weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine. HIV Clin Trials. 2015 Aug; 16(4):125-9. PMID: 26133089.
      Citations:    
    15. Rudy BJ, Kapogiannis BG, Worrell C, Squires K, Bethel J, Li S, Wilson CM, Agwu A, Emmanuel P, Price G, Hudey S, Goodenow MM, Sleasman JW. Immune Reconstitution but Persistent Activation After 48 Weeks of Antiretroviral Therapy in Youth With Pre-Therapy CD4 >350 in ATN 061. J Acquir Immune Defic Syndr. 2015 May 1; 69(1):52-60. PMID: 25942459.
      Citations:    
    16. Markowitz M, Zolopa A, Squires K, Ruane P, Coakley D, Kearney B, Zhong L, Wulfsohn M, Miller MD, Lee WA. Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults. J Antimicrob Chemother. 2014 May; 69(5):1362-9. PMID: 24508897.
      Citations:    
    17. Squires K, Feinberg J, Bridge DA, Currier J, Ryan R, Seyedkazemi S, Dayaram YK, Mrus J. Insights on GRACE (Gender, Race, And Clinical Experience) from the Patient's Perspective: GRACE Participant Survey. AIDS Patient Care STDS. 2013 Jun; 27(6):352-62. PMID: 23701200.
      Citations:    
    18. Kahn JA, Xu J, Kapogiannis BG, Rudy B, Gonin R, Liu N, Wilson CM, Worrell C, Squires KE. Immunogenicity and Safety of the Human Papillomavirus 6, 11, 16, 18 Vaccine in HIV-Infected Young Women. Clin Infect Dis. 2013 Sep; 57(5):735-44. PMID: 23667266.
      Citations:    
    19. Schafer JJ, Manlangit K, Squires KE. Bone health and human immunodeficiency virus infection. Pharmacotherapy. 2013 Jun; 33(6):665-82. PMID: 23553497.
      Citations:    
    20. Shah BM, Schafer JJ, Priano J, Squires KE. Cobicistat: a new boost for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2013 Oct; 33(10):1107-16. PMID: 23471741.
      Citations:    
    21. Squires KE, Bekker LG, Eron JJ, Cheng B, Rockstroh JK, Marquez F, Kumar P, Thompson M, Campo RE, Mounzer K, Strohmaier KM, Lu C, Rodgers A, Jackson BE, Wenning LA, Robertson M, Nguyen BY, Sklar For The Realmrk Investigators P. Safety, Tolerability, and Efficacy of Raltegravir in a Diverse Cohort of HIV-Infected Patients: 48-Week Results from the REALMRK Study. AIDS Res Hum Retroviruses. 2013 Jun; 29(6):859-70. PMID: 23351187.
      Citations:    
    22. Young B, Squires KE, Ross LL, Santiago L, Sloan LM, Zhao HH, Wine BC, Pakes GE, Margolis DA, Shaefer MS. Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES. AIDS Res Hum Retroviruses. 2013 Feb; 29(2):350-8. PMID: 23039030.
      Citations:    
    23. Kahn JA, Burk RD, Squires KE, Kapogiannis BG, Rudy B, Xu J, Gonin R, Liu N, Worrell C, Wilson CM. Prevalence and risk factors for HPV in HIV-positive young women receiving their first HPV vaccination. J Acquir Immune Defic Syndr. 2012 Nov 1; 61(3):390-9. PMID: 22820809.
      Citations:    
    24. Squires KE, Young B, DeJesus E, Bellos N, Murphy D, Ward D, Zhao HH, Ross LL, Shaefer MS. ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudine. HIV Clin Trials. 2012 Sep-Oct; 13(5):233-44. PMID: 23134624.
      Citations:    
    25. Smith KY, Garcia F, Kumar P, Currier JS, Ryan R, Falcon R, Mrus J, Squires K. Assessing darunavir/ritonavir-based therapy in a racially diverse population: 48-week outcomes from GRACE. J Natl Med Assoc. 2012 Jul-Aug; 104(7-8):366-76. PMID: 23092052.
      Citations:    
    26. Kahn JA, Xu J, Zimet GD, Liu N, Gonin R, Dillard ME, Squires K. Risk perceptions after human papillomavirus vaccination in HIV-infected adolescents and young adult women. J Adolesc Health. 2012 May; 50(5):464-70. PMID: 22525109.
      Citations:    
    27. Feinberg J, Saag M, Squires K, Currier J, Ryan R, Coate B, Mrus J. Health-related quality of life in the gender, race, and clinical experience trial. AIDS Res Treat. 2011; 2011:349165. PMID: 21904672.
      Citations:    
    28. Hirani A, Cavallazzi R, Vasu T, Pachinburavan M, Kraft WK, Leiby B, Short W, Desimone J, Squires KE, Weibel S, Kane GC. Prevalence of obstructive lung disease in HIV population: a cross sectional study. Respir Med. 2011 Nov; 105(11):1655-61. PMID: 21703841.
      Citations:    
    29. Falcon R, Bridge DA, Currier J, Squires K, Hagins D, Schaible D, Ryan R, Mrus J. Recruitment and retention of diverse populations in antiretroviral clinical trials: practical applications from the gender, race and clinical experience study. J Womens Health (Larchmt). 2011 Jul; 20(7):1043-50. PMID: 21663416.
      Citations:    
    30. Squires KE, Hodder SL, Feinberg J, Bridge DA, Abrams S, Storfer SP, Aberg JA. Health needs of HIV-infected women in the United States: insights from the women living positive survey. AIDS Patient Care STDS. 2011 May; 25(5):279-85. PMID: 21446785.
      Citations:    
    31. Squires KE, Johnson M, Yang R, Uy J, Sheppard L, Absalon J, McGrath D. Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study. J Antimicrob Chemother. 2011 Feb; 66(2):363-70. PMID: 21148235.
      Citations:    
    32. Hammer SM, Ribaudo H, Bassett R, Mellors JW, Demeter LM, Coombs RW, Currier J, Morse GD, Gerber JG, Martinez AI, Spreen W, Fischl MA, Squires KE. A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen. HIV Clin Trials. 2010 Nov-Dec; 11(6):312-24. PMID: 21239359.
      Citations:    
    33. Schafer JJ, Short WR, Squires KE. Association between abacavir exposure and increased risk for cardiovascular disease in patients with human immunodeficiency virus. Pharmacotherapy. 2010 Oct; 30(10):1072-83. PMID: 20874044.
      Citations:    
    34. Saag MS, Squires KE, Aberg JA, Bardeguez A. Letter in response to the new SHEA guideline for healthcare workers with hepatitis B virus, hepatitis C virus, and/or human immunodeficiency virus. Infect Control Hosp Epidemiol. 2010 Oct; 31(10):1092-3; author reply 1093-5. PMID: 20812818.
      Citations:    
    35. Currier J, Averitt Bridge D, Hagins D, Zorrilla CD, Feinberg J, Ryan R, Falcon R, Tennenberg A, Mrus J, Squires K. Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. Ann Intern Med. 2010 Sep 21; 153(6):349-57. PMID: 20855799.
      Citations:    
    36. Squires KE, Young B, Dejesus E, Bellos N, Murphy D, Zhao HH, Patel LG, Ross LL, Wannamaker PG, Shaefer MS. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. AIDS. 2010 Aug 24; 24(13):2019-27. PMID: 20613461.
      Citations:    
    37. Squires KE, Young B, DeJesus E, Bellos N, Murphy D, Sutherland-Phillips DH, Zhao HH, Patel LG, Ross LL, Wannamaker PG, Shaefer MS. Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patients. HIV Clin Trials. 2010 Mar-Apr; 11(2):69-79. PMID: 20542844.
      Citations:    
    38. Schafer JJ, Squires KE. Integrase inhibitors: a novel class of antiretroviral agents. Ann Pharmacother. 2010 Jan; 44(1):145-56. PMID: 20040702.
      Citations:    
    39. Fife KH, Wu JW, Squires KE, Watts DH, Andersen JW, Brown DR. Prevalence and persistence of cervical human papillomavirus infection in HIV-positive women initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2009 Jul 1; 51(3):274-82. PMID: 19387354.
      Citations:    
    40. Lubinski C, Aberg J, Bardeguez AD, Elion R, Emmanuel P, Kuritzkes D, Saag M, Squires KE, Weddle A, Rainey J, Zerehi MR, Ralston JF, Fleming DA, Bronson D, Cooke M, Cutler C, Ejnes Y, Gluckman R, Liebow M, Musana K, Mayer ME, Purtle MW, Reynolds PP, Viswanathan L, Weiss KB, Yehia B. HIV policy: the path forward--a joint position paper of the HIV Medicine Association of the Infectious Diseases Society of America and the American College of Physicians. Clin Infect Dis. 2009 May 15; 48(10):1335-44. PMID: 19385087.
      Citations:    
    41. Jordan PS, Poon A, Eron J, Squires K, Ignacio C, Richman DD, Smith DM. A novel codon insert in protease of clade B HIV type 1. AIDS Res Hum Retroviruses. 2009 May; 25(5):547-50. PMID: 19397401.
      Citations:    
    42. Walmsley SL, Squires K, Weiss L, Easterbrook P, Orani A, Kraft M, Scherer J. Multidrug-experienced HIV-1-infected women demonstrated similar virological and immunological responses to tipranavir/ritonavir compared with men. AIDS. 2009 Jan 28; 23(3):429-31. PMID: 19114862.
      Citations:    
    43. Stein JH, Komarow L, Cotter BR, Currier JS, Dubé MP, Fichtenbaum CJ, Gerschenson M, Mitchell CK, Murphy RL, Squires K, Parker RA, Torriani FJ. Lipoprotein Changes in HIV-Infected Antiretroviral-Naïve Individuals after Starting Antiretroviral Therapy: ACTG Study A5152s Stein: Lipoprotein Changes on Antiretroviral Therapy. J Clin Lipidol. 2008 Dec; 2(6):464-471. PMID: 19956354.
      Citations:    
    44. Belden KA, Squires KE. HIV infection in women: do sex and gender matter? Curr Infect Dis Rep. 2008 Sep; 10(5):423-31. PMID: 18687207.
      Citations:    
    45. Young B, Squires K, Patel P, Dejesus E, Bellos N, Berger D, Sutherland-Phillips DH, Liao Q, Shaefer M, Wannamaker P. First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America. AIDS. 2008 Aug 20; 22(13):1673-5. PMID: 18670229.
      Citations:    
    46. Torriani FJ, Komarow L, Parker RA, Cotter BR, Currier JS, Dubé MP, Fichtenbaum CJ, Gerschenson M, Mitchell CK, Murphy RL, Squires K, Stein JH. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol. 2008 Aug 12; 52(7):569-76. PMID: 18687253.
      Citations:    
    47. Grinspoon SK, Grunfeld C, Kotler DP, Currier JS, Lundgren JD, Dubé MP, Lipshultz SE, Hsue PY, Squires K, Schambelan M, Wilson PW, Yarasheski KE, Hadigan CM, Stein JH, Eckel RH. State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary. Circulation. 2008 Jul 8; 118(2):198-210. PMID: 18566320.
      Citations:    
    48. Sansom SL, Anthony MN, Garland WH, Squires KE, Witt MD, Kovacs Andrea A, Larsen RA, Valencia R, Pals SL, Hader S, Weidle PJ, Wohl AR. The costs of HIV antiretroviral therapy adherence programs and impact on health care utilization. AIDS Patient Care STDS. 2008 Feb; 22(2):131-8. PMID: 18260804.
      Citations:    
    49. Demeter LM, DeGruttola V, Lustgarten S, Bettendorf D, Fischl M, Eshleman S, Spreen W, Nguyen BY, Koval CE, Eron JJ, Hammer S, Squires K. Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. HIV Clin Trials. 2008 Jan-Feb; 9(1):11-25. PMID: 18215978.
      Citations:    
    50. Squires KE. Gender differences in the diagnosis and treatment of HIV. Gend Med. 2007 Dec; 4(4):294-307. PMID: 18215722.
      Citations:    
    51. Huang J, Wang F, Argyris E, Chen K, Liang Z, Tian H, Huang W, Squires K, Verlinghieri G, Zhang H. Cellular microRNAs contribute to HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med. 2007 Oct; 13(10):1241-7. PMID: 17906637.
      Citations:    
    52. Campo RE, Narayanan S, Clay PG, Dehovitz J, Johnson D, Jordan W, Squires KE, Sajjan SG, Markson LE. Factors influencing the acceptance of changes in antiretroviral therapy among HIV-1-infected patients. AIDS Patient Care STDS. 2007 May; 21(5):329-38. PMID: 17518525.
      Citations:    
    53. Gulick RM, Lalama CM, Ribaudo HJ, Shikuma CM, Schackman BR, Schouten J, Squires KE, Koletar SL, Pilcher CD, Reichman RC, Klingman KL, Kuritzkes DR. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression. AIDS. 2007 Apr 23; 21(7):813-23. PMID: 17415036.
      Citations:    
    54. Kuritzkes DR, Ribaudo HJ, Squires KE, Koletar SL, Santana J, Riddler SA, Reichman R, Shikuma C, Meyer WA, Klingman KL, Gulick RM. Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s. J Infect Dis. 2007 Apr 15; 195(8):1169-76. PMID: 17357053.
      Citations:    
    55. Squires KE. Women and HIV: a population at risk. Res Initiat Treat Action. 2007; 12(2):18-20. PMID: 17489118.
      Citations:    
    56. Verma S, Bhakta H, Nowain A, Kanel G, Squires K. Occult hepatic opportunistic infection (OI) and highly active antiretroviral therapy (HAART) induced immune reconstitution: an important cause of jaundice in a patient with AIDS. AIDS Res Hum Retroviruses. 2006 Oct; 22(10):1052-3. PMID: 17067277.
      Citations:    
    57. Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer WA, Acosta EP, Schouten J, Squires KE, Pilcher CD, Murphy RL, Koletar SL, Carlson M, Reichman RC, Bastow B, Klingman KL, Kuritzkes DR. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA. 2006 Aug 16; 296(7):769-81. PMID: 16905783.
      Citations:    
    58. Squires KE. Editorial comment: women and HIV--a population at risk. AIDS Read. 2006 Jul; 16(7):374-5. PMID: 16874917.
      Citations:    
    59. Wohl AR, Garland WH, Valencia R, Squires K, Witt MD, Kovacs A, Larsen R, Hader S, Anthony MN, Weidle PJ. A randomized trial of directly administered antiretroviral therapy and adherence case management intervention. Clin Infect Dis. 2006 Jun 1; 42(11):1619-27. PMID: 16652320.
      Citations:    
    60. Giordano M, Kelleher T, Colonno RJ, Lazzarin A, Squires K. The effects of the Roche AMPLICOR HIV-1 MONITOR UltraSensitive Test versions 1.0 and 1.5 viral load assays and plasma collection tube type on determination of response to antiretroviral therapy and the inappropriateness of cross-study comparisons. J Clin Virol. 2006 Apr; 35(4):420-5. PMID: 16604577.
      Citations:    
    61. Verma S, Wang CH, Govindarajan S, Kanel G, Squires K, Bonacini M. Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients? Clin Infect Dis. 2006 Jan 15; 42(2):262-70. PMID: 16355339.
      Citations:    
    62. Verma S, Bhakta H, Nowain A, Pais S, Kanel G, Squires K. Severe cholestatic liver injury days after initiating antiretroviral therapy in a patient with AIDS: drug toxicity or immune reconstitution inflammatory syndrome? Dig Dis Sci. 2005 Oct; 50(10):1813-7. PMID: 16187179.
      Citations:    
    63. Squires KE. Editorial comment: HIV-infected women require a range of specialized services. AIDS Read. 2005 Aug; 15(8):426. PMID: 16114128.
      Citations:    
    64. Clark RA, Squires KE. Gender-specific considerations in the antiretroviral management of HIV-infected women. Expert Rev Anti Infect Ther. 2005 Apr; 3(2):213-27. PMID: 15918779.
      Citations:    
    65. Squires K, Lazzarin A, Gatell JM, Powderly WG, Pokrovskiy V, Delfraissy JF, Jemsek J, Rivero A, Rozenbaum W, Schrader S, Sension M, Vibhagool A, Thiry A, Giordano M. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr. 2004 Aug 15; 36(5):1011-9. PMID: 15247553.
      Citations:    
    66. Cahn PE, Gatell JM, Squires K, Percival LD, Piliero PJ, Sanne IA, Shelton S, Lazzarin A, Odeshoo L, Kelleher TD, Thiry A, Giordano MD, Schnittman SM. Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials. J Int Assoc Physicians AIDS Care (Chic). 2004 Jul-Sep; 3(3):92-8. PMID: 15573713.
      Citations:    
    67. Wohl AR, Garland WH, Squires K, Witt M, Larsen R, Kovacs A, Hader S, Weidle PJ. The feasibility of a community-based directly administered antiretroviral therapy program. Clin Infect Dis. 2004 Jun 1; 38 Suppl 5:S388-92. PMID: 15156427.
      Citations:    
    68. Monteiro CA, Bachmann LH, Desmond RA, Squires KE, Vermund SH, Hook EW, Schwebke JR, Hoesley CJ. Incidence and risk factors for sexually transmitted infections among women in an Alabama HIV clinic. AIDS Res Hum Retroviruses. 2004 Jun; 20(6):577-83. PMID: 15242532.
      Citations:    
    69. Vogler MA, Teppler H, Gelman R, Valentine F, Lederman MM, Pomerantz RJ, Pollard RB, Cherng DW, Gonzalez CJ, Squires KE, Frank I, Mildvan D, Mahon LF, Schock B. Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248). J Acquir Immune Defic Syndr. 2004 May 1; 36(1):576-87. PMID: 15097300.
      Citations:    
    70. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Squires KE, Meyer WA, Acosta EP, Schackman BR, Pilcher CD, Murphy RL, Maher WE, Witt MD, Reichman RC, Snyder S, Klingman KL, Kuritzkes DR. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med. 2004 Apr 29; 350(18):1850-61. PMID: 15115831.
      Citations:    
    71. Hammer SM, Bassett R, Squires KE, Fischl MA, Demeter LM, Currier JS, Mellors JW, Morse GD, Eron JJ, Santana JL, DeGruttola V. A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir. Antivir Ther. 2003 Dec; 8(6):507-18. PMID: 14760884.
      Citations:    
    72. Hirsch MS, Steigbigel RT, Staszewski S, McMahon D, Fischl MA, Hirschel B, Squires K, DiNubile MJ, Harvey CM, Chen J, Leavitt RY. Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infection. Clin Infect Dis. 2003 Oct 15; 37(8):1119-24. PMID: 14523778.
      Citations:    
    73. Squires K, Pozniak AL, Pierone G, Steinhart CR, Berger D, Bellos NC, Becker SL, Wulfsohn M, Miller MD, Toole JJ, Coakley DF, Cheng A. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med. 2003 Sep 2; 139(5 Pt 1):313-20. PMID: 12965939.
      Citations:    
    74. DiCenzo R, Forrest A, Squires KE, Hammer SM, Fischl MA, Wu H, Cha R, Morse GD. Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother. 2003 Jun; 47(6):1929-35. PMID: 12760869.
      Citations:    
    75. Wohl AR, Lu S, Turner J, Kovacs A, Witt M, Squires K, Towner W, Beer V. Risk of opportunistic infection in the HAART era among HIV-infected Latinos born in the United States compared to Latinos born in Mexico and Central America. AIDS Patient Care STDS. 2003 Jun; 17(6):267-75. PMID: 12880490.
      Citations:    
    76. van Leeuwen R, Katlama C, Murphy RL, Squires K, Gatell J, Horban A, Clotet B, Staszewski S, van Eeden A, Clumeck N, Moroni M, Pavia AT, Schmidt RE, Gonzalez-Lahoz J, Montaner J, Antunes F, Gulick R, Bánhegyi D, van der Valk M, Reiss P, van Weert L, van Leth F, Johnson VA, Sommadossi JP, Lange JM. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS. 2003 May 2; 17(7):987-99. PMID: 12700448.
      Citations:    
    77. Squires KE. Treating HIV infection and AIDS in women. AIDS Read. 2003 May; 13(5):228-34, 239-40. PMID: 12800826.
      Citations:    
    78. Kuritzkes DR, Boyle BA, Gallant JE, Squires KE, Zolopa A. Current management challenges in HIV: antiretroviral resistance. AIDS Read. 2003 Mar; 13(3):133-5, 138-42. PMID: 12728868.
      Citations:    
    79. Wright PW, Hoesley CJ, Squires KE, Croom-Rivers A, Weiss HL, Gnann JW. A prospective study of genital herpes simplex virus type 2 infection in human immunodeficiency virus type 1 (HIV-1)-seropositive women: correlations with CD4 cell count and plasma HIV-1 RNA level. Clin Infect Dis. 2003 Jan 15; 36(2):207-11. PMID: 12522754.
      Citations:    
    80. Viscidi RP, Ahdieh-Grant L, Clayman B, Fox K, Massad LS, Cu-Uvin S, Shah KV, Anastos KM, Squires KE, Duerr A, Jamieson DJ, Burk RD, Klein RS, Minkoff H, Palefsky J, Strickler H, Schuman P, Piessens E, Miotti P. Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women. J Infect Dis. 2003 Jan 15; 187(2):194-205. PMID: 12552444.
      Citations:    
    81. Sanne I, Piliero P, Squires K, Thiry A, Schnittman S. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr. 2003 Jan 1; 32(1):18-29. PMID: 12514410.
      Citations:    
    82. Riddler SA, Havlir D, Squires KE, Kerr B, Lewis RH, Yeh K, Wynne LH, Zhong L, Peng Y, Deutsch P, Saah A. Coadministration of indinavir and nelfinavir in human immunodeficiency virus type 1-infected adults: safety, pharmacokinetics, and antiretroviral activity. Antimicrob Agents Chemother. 2002 Dec; 46(12):3877-82. PMID: 12435691.
      Citations:    
    83. Cohen C, Elion RA, Frank I, Kloser P, Sherer R, Squires KE, Steinhart C, Tebas P. Once-daily antiretroviral therapies for HIV infection: Consensus Statement of an Advisory Committee of the International Association of Physicians in AIDS Care. J Int Assoc Physicians AIDS Care (Chic). 2002 Oct-Dec; 1(4):141-5. PMID: 12942673.
      Citations:    
    84. Skowron G, Kuritzkes DR, Thompson MA, Squires KE, Goodwin SD, Dusak BA, Tolson JM, Stevens M, Yuen GJ, Rooney JF. Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients. J Infect Dis. 2002 Oct 1; 186(7):1028-33. PMID: 12232846.
      Citations:    
    85. Hoesley CJ, Allen SA, Raper JL, Musonda R, Niu Y, Gao F, Squires KE, Aldrovandi GM. Comparative analysis of commercial assays for the detection and quantification of Human Immunodeficiency Virus Type 1 (HIV-1) RNA in plasma from patients infected with HIV-1 subtype C. Clin Infect Dis. 2002 Aug 1; 35(3):323-5. PMID: 12115099.
      Citations:    
    Squires's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (220)
    Explore
    _
    Co-Authors (8)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _